About Rivaara Labs
Rivaara Labs is a company based in Mumbai (India) founded in 2019 by Bharat Daftary. Rivaara Labs has raised $9.89 million across 2 funding rounds from investors including Kotak Mahindra Bank, Amicus Capital Partners and Bharat Daftary. The company has 143 employees as of April 06, 2024. Rivaara Labs offers products and services including RespiQuik Panels, SeptiQuik Panels, MeningoQuik Panels, Tuberculosis Panels, and HPV & LBC Panels. Rivaara Labs operates in a competitive market with competitors including Dr Lal PathLabs, Redcliffe Labs, Sterling Accuris Diagnostics, Orange health and Metropolis India, among others.
- Headquarter Mumbai, India
- Employees 143 as on 06 Apr, 2024
- Founders Bharat Daftary
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rivaara Labs Private Limited
- Date of Incorporation 18 Oct, 2019
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$2.81 M (USD)-39.42as on Mar 31, 2023
-
Net Profit
-$4.19 M (USD)-39.16as on Mar 31, 2023
-
EBITDA
-$3.35 M (USD)-41.24as on Mar 31, 2023
-
Total Equity Funding
$9.89 M (USD)
in 2 rounds
-
Latest Funding Round
$2.59 M (USD), Series A
Aug 18, 2023
-
Investors
Kotak Mahindra Bank
& 2 more
-
Employee Count
143
as on Apr 06, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rivaara Labs
Rivaara Labs offers a comprehensive portfolio of products and services, including RespiQuik Panels, SeptiQuik Panels, MeningoQuik Panels, Tuberculosis Panels, and HPV & LBC Panels.
Tests for respiratory infections and pathogens
Detects sepsis-related bacteria and fungi
Identifies meningitis and encephalitis pathogens
Screens for tuberculosis and drug resistance
Detects human papillomavirus and related conditions
Provides tests for cancer detection and monitoring
People of Rivaara Labs
Unlock access to complete
Funding Insights of Rivaara Labs
Rivaara Labs has successfully raised a total of $9.89M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.59 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rivaara Labs
Rivaara Labs has secured backing from 3 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Amicus Capital Partners and Bharat Daftary.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment services in financial services, consumer, healthcare, technology, and manufacturing sectors.
|
Locked | Locked | Locked | |
|
Commercial banking services are offered to corporate and retail customers.
|
Locked | Locked | Locked | |
|
BD
Bharat Daftary |
-
|
Locked | Locked | Locked |
Investor details for Rivaara Labs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rivaara Labs
Investment portfolio details for Rivaara Labs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rivaara Labs
Detailed financials for Rivaara Labs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rivaara Labs Comparisons
Peer comparison for Rivaara Labs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rivaara Labs
Rivaara Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Dr Lal PathLabs, Redcliffe Labs, Sterling Accuris Diagnostics, Orange health and Metropolis India, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Chain of pathology and radiology labs
|
|
| Locked | Locked | Locked |
Home-based diagnostic tests are booked via an online platform.
|
|
| Locked | Locked | Locked |
Pathology diagnostic services are offered via a chain of labs.
|
|
| Locked | Locked | Locked |
At-home diagnostic tests are booked and collected by phlebotomists.
|
|
| Locked | Locked | Locked |
Diagnostic centers are operated as a nationwide chain.
|
|
| Locked | Locked | Locked |
Leading diagnostic chain providing quality blood test and full body checkup services
|
Detailed competitors of Rivaara Labs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rivaara Labs
Complete news archive for Rivaara Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rivaara Labs
Rivaara Labs was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Rivaara Labs is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Rohit Seshadri is the current CEO of Rivaara Labs.
Rivaara Labs is a funded company, having raised a total of $9.89M across 2 funding rounds to date.
As of Apr 06, 2024, the latest employee count at Rivaara Labs is 143.
Annual revenue of Rivaara Labs is $2.81M as on Mar 31, 2023.
Rivaara Labs was founded in 2019 and is based in Mumbai, India, within the molecular diagnostics sector. PCR-based test kits are developed by the company for detecting prevalent pathogens and supporting effective treatments. A network of specialized molecular diagnostics labs is being established, along with national reference labs. Novel point-of-care solutions are marketed to expand diagnostic access.
Rivaara Labs's top competitors include Dr Lal PathLabs, Redcliffe Labs and Metropolis India.
Rivaara Labs offers RespiQuik Panels, SeptiQuik Panels, MeningoQuik Panels, Tuberculosis Panels, and 2 more products and services.
Rivaara Labs has 3 investors. Key investors include Kotak Mahindra Bank, Amicus Capital Partners, and Bharat Daftary.
The valuation of Rivaara Labs is $21.44M as of Aug 2023.